GlassScriptPhysician profile
Laura A Knecht
NPI 1477752236
$141,786.98
in general payments reported to CMS, 2019-2025
26 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115K · 2020: $27K · 2022: $46.85 · 2024: $172 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $273.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $128,937.26 | 2019-2025 | Korlym |
| Ipsen Biopharmaceuticals, INC | $11,279.21 | 2019-2020 | |
| Lilly USA, LLC | $248.39 | 2019-2020 | |
| Abbott Laboratories | $149.89 | 2019-2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $132.60 | 2019-2020 | |
| Mannkind Corporation | $126.94 | 2019 | |
| Insulet Corporation | $118.70 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $109.17 | 2019 | |
| Amgen INC. | $106.91 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $80.45 | 2019 | |
| Novo Nordisk INC | $67.94 | 2019-2020 | |
| Pfizer INC. | $61.83 | 2019-2020 | |
| Abbvie INC. | $53.70 | 2019 | |
| Amneal Pharmaceuticals LLC | $45.62 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $41.59 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $34.87 | 2019 | |
| Companion Medical, INC. | $33.19 | 2019-2020 | |
| Vivus LLC | $28.75 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $22.15 | 2019 | |
| Horizon Therapeutics Plc | $20.64 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $19.40 | 2019 | |
| Tandem Diabetes Care, INC. | $16.16 | 2019 | |
| Shire North American Group INC | $15.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.87 | 2019 | |
| Valeritas, INC. | $11.53 | 2019 | |
| Ibsa Pharma INC. | $11.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Knecht listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.